drugset / Trial / NCT05642806

Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment

NCT05642806

Phase 4 Unknown 90 enrolled St. Paul's Sinus Centre
RandomizedParallel-groupTriple-blindTreatment

Summary

This study aims to analyze the immune profiles of patients with Chronic Rhinosinusitis with Nasal polyps (CRSwNP) with and without asthma before and after Mepolizumab. A group of participants with CRS without nasal polyps (CRSsNP) with asthma will be included to compare their immune profiles to CRSwNP.

Timeline

Start
2023-07-01
Primary completion
2024-12-30
Completion
2025-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Mepolizumab Monoclonal antibody 100 mg Subcutaneous